

ISD Immunotech expands management team with new Chief Executive Officer

COPENHAGEN, DENMARK, May 9, 2022

ISD Immunotech (“ISD”), a private biotechnology company developing targeted therapies for severe autoimmune diseases treatment including systemic lupus erythematosus (SLE) today announced the appointment of Gert Bolwig, PhD as the company's Chief Executive Officer, effective immediately.

Dr. Bolwig will be succeeding the industry veteran Ms. Ingelise Saunders who has acted as Executive Chairman. Ms. Saunders will continue as Chairman of the Board. Dr. Bolwig brings expertise in business development, fundraising and program management. He has more than two decades of industry and leadership experience from Biotech and Pharma, including Orphazyme and Nycomed. He is also an investment advisor for a life science fund and has been a consultant for a several biotech companies.

“We are delighted to have Gert join our company,” said Ingelise Saunders, Chairman of the Board. “Gert is an experienced life science professional who complements the team and is perfectly positioned to lead the company.”

“I am privileged to join ISD at this exciting time, said Gert Bolwig. The team has produced outstanding work and built a global network of world-class scientific and medical advisors. We now look forward to executing our plan to hopefully provide the sufferers of this very serious chronic disease, most of whom are women of child-bearing age, with a new and efficacious treatment option.”

About ISD Immunotech

ISD Immunotech is a private preclinical biotech focusing on the development of a peptide therapeutic, ISD017, which uniquely blocks all aspects of STING pathway overactivation in severe SLE (lupus).

The company, headquartered in Copenhagen, is a spinout of Aarhus University, Denmark, which is an academic center of excellence in STING biology. The company is supported by world class academic and clinical advisors with deep insight into STING biology, animal disease models and clinical lupus research. The company is funded by Novo Seeds and Eir Ventures.

For more details, please visit www.isd-immunotech.com

Gert Bolwig, CEO

ISD-Immunotech

info@isd-immunotech.com